← Back to list
08.00.13am, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)
Effective date
Jan 1, 2026
Identified
Jun 19, 2026
Summary
Independence Blue Cross updated IVIG/SCIG policy 08.00.13am to version 08.00.13ao effective 01/01/2026, designating most IVIG products as preferred except Asceniv, Panzga, and Alyglo. The policy added new IVIG product Yimmugo (J1599) and initially removed HCPCS codes J1562 and J1572, but on 01/13/2026 reversed course to reinstate J1572 per CMS guidance. Billing teams must update systems to reflect current preferred/non-preferred IVIG product status and ensure correct code usage.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
Action · 5 steps
01By 01/01/2026: Billing team must update claims processing system to recognize Yimmugo as a preferred IVIG product and ensure J1599 is active in the billing system.
02Update preferred/non-preferred drug list to reflect that Asceniv, Panzga, and Alyglo are non-preferred IVIG products, which may trigger higher member cost-sharing or require prior authorization.
03On or before 01/13/2026: Billing team must immediately reinstate HCPCS code J1572 (Flebogamma/Flebogamma DIF) in the billing system after the CMS guidance correction—do not process claims using J1572 as deleted.
04Verify that J1562 (Vivaglobin) remains removed per the 01/01/2026 policy version.
05Update all billing staff on the preferred product list to ensure accurate prior authorization denials.
If missed: Failure to process preferred products correctly will result in inappropriate patient cost-sharing; failure to bill reinstated J1572 will result in claim denials.
Codes mentioned
J1599J1562J1572J1555J1558J1559J1561J1569J1575
Original notice
08.00.13am, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →MA08.009w, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)MediumEffective Jan 1, 2025 · Medical PolicyMA08.009y, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)MediumEffective Apr 1, 2026 · Medical PolicyMA08.009z, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)LowEffective Jul 1, 2026 · Medical Policy08.00.13ao, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)LowEffective Jul 1, 2026 · Medical PolicyBrowse every Independence Blue Cross change in the policy list